Human Treg responses allow sustained recombinant adeno-associated virus–mediated transgene expression
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors have shown promise for the treatment of several diseases; however, immune-mediated elimination of transduced cells has been suggested to limit and account for a loss of efficacy. To determine whether rAAV vector expression can persist long term, we administered rAAV vectors expressing normal, M-type α-1 antitrypsin (M-AAT) to AAT-deficient subjects at various doses by multiple i.m. injections. M-specific AAT expression was observed in all subjects in a dose-dependent manner and was sustained for more than 1 year in the absence of immune suppression. Muscle biopsies at 1 year had sustained AAT expression and a reduction of inflammatory cells compared with 3 month biopsies. Deep sequencing of the TCR Vβ region from muscle biopsies demonstrated a limited number of T cell clones that emerged at 3 months after vector administration and persisted for 1 year. In situ immunophenotyping revealed a substantial Treg population in muscle biopsy samples containing AAT-expressing myofibers. Approximately 10% of all T cells in muscle were natural Tregs, which were activated in response to AAV capsid. These results suggest that i.m. delivery of rAAV type 1-AAT (rAAV1-AAT) induces a T regulatory response that allows ongoing transgene expression and indicates that immunomodulatory treatments may not be necessary for rAAV-mediated gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regulatory T cells (Treg) modulate immune tolerance towards transgene product and capsid that are vital to durable expression of therapeutic protein (16, 17).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This long-term expression was attributed to the induction of regulatory T cells (Tregs) in the muscles of AAV-injected patients.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“whereas muscle-directed AAV gene therapy clinical trials have shown long-lived transgene expression and induction of Tregs.7,8,11,51”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [11]
In the citing paper
“Tolerance induction and long-term expression of transgene in local muscle-directed AAV gene therapy was attributed to Tregs due to their ability to suppress immune responses [92].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [92]
In the citing paper
“Infiltration of CD4+ forkhead box P3+ (FoxP3) T cells, in addition to CD8+ T cells, was reported in α1-antitrypsin (AAT) deficiency and Glybera studies [92, 93].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [92]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“The long-lasting presence of rAAV1 capsid may in some ways mimic a chronic viral infection, which has been shown to induce Treg responses (17) along with what has been termed “exhausted” T cells.”
BackgroundRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 2×
“Interestingly, expression of PD-1 and PD-L1, which is associated with chronic viral infection and exhausted T cell responses (18–20), was also observed in many of the inflammatory foci of the rAAV-injected muscles.”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“(6), in a liver-directed hemophilia B trial, a modest immune modulation (60 mg prednisolone daily with tapering and discontinuation over 4 to 7 weeks) was sufficient to enhance gene expression and decrease transaminase elevation.”
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide
Jordan, M. S., Boesteanu, A., Reed, A. J., Petrone, A. L., Holenbeck, A. E., Lerman, M. A., Naji, A., & Caton, A. J. (2001) · Nature Immunology · doi:10.1038/86302 · Cited by 1,660 · cited 1×
“It is known that natural Tregs (CD4+CD25+FOXP3+) arise in the thymus during development and are thought to possess T cell receptors specific for self antigens (26).”
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Redefining Chronic Viral Infection
Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“However, the significance of anti-capsid effector T cell responses is unclear, and at least some studies have suggested that they target transduced cells and limit the duration of transgene expression (9, 10).”
BackgroundLeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Self-citationReinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
Freeman, G. J., Wherry, E. J., Ahmed, R., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061800 · Cited by 399 · cited 1×
“In this way, the PD-1/PD-L1 pathway contributes directly to T cell exhaustion during chronic infections, as it remains expressed at high levels in the setting of persistent antigen (21).”
BackgroundWeiss, L., Donkova-Petrini, V., Caccavelli, L., Balbo, M., Carbonneil, C., & Levy, Y. (2004) · Blood · doi:10.1182/blood-2004-01-0365 · Cited by 384
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335 · cited 7×
“Cellular infiltrates consisting primarily of lymphocytes were observed at the injection site at 90 days after administration, as previously reported (14), and were also observed at 1 year after injection in all patients (Figure 2).”
BackgroundMethodInfluentialSelf-citationBrantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · cited 3×
“injection, which has persisted in individuals despite the emergence of anti-capsid effector T cells (which have included both CD4+ and CD8+ cells, with CD8+ population cells having markers consistent with cytotoxic T cells) (13, 14).”
BackgroundMethodSelf-citationMacDonald, A. J., Duffy, M., Brady, M. T., McKiernan, S., Hall, W., Hegarty, J., Curry, M., & Mills, K. H. G. (2002) · The Journal of Infectious Diseases · doi:10.1086/339340 · Cited by 239
Kaufmann, D. E., & Walker, B. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803771 · Cited by 229 · cited 2×
“Interestingly, expression of PD-1 and PD-L1, which is associated with chronic viral infection and exhausted T cell responses (18–20), was also observed in many of the inflammatory foci of the rAAV-injected muscles.”
van der Burg, S. H., Piersma, S. J., de Jong, A., van der Hulst, J. M., Kwappenberg, K. M. C., van den Hende, M., Welters, M. J. P., Van Rood, J. J., Fleuren, G. J., Melief, C. J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704672104 · Cited by 217
Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 1×
“However, the significance of anti-capsid effector T cell responses is unclear, and at least some studies have suggested that they target transduced cells and limit the duration of transgene expression (9, 10).”
BackgroundBrantly, M. L., Spencer, L. T., Humphries, M., Conlon, T. J., Spencer, C. T., Poirier, A., Garlington, W., Baker, D., Song, S., Berns, K. I., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1177 · Cited by 177 · cited 1×
“injection of a rAAV serotype 2–AAT vector (11, 12) and subsequently using a cross-packaged rAAV serotype 1–AAT vector (rAAV1-AAT) in phase I and phase II clinical trials (13, 14) Published results from both of the rAAV1-AAT trials have shown a dose-dependent increase in serum levels of wild-type–specific AAT (M-AAT) l…”
MethodSelf-citationEbinuma, H., Nakamoto, N., Li, Y., Price, D. A., Gostick, E., Levine, B. L., Tobias, J., Kwok, W. W., & Chang, K.-M. (2008) · Journal of Virology · doi:10.1128/jvi.01548-07 · Cited by 161 · cited 1×
“While the mechanism remains elusive, it is clear that virus-specific natural Tregs allowing viral persistence have been observed in humans with chronic hepatitis C virus (29, 30).”
Background(2004) · Human Gene Therapy · doi:10.1089/10430340460732490 · Cited by 146 · cited 1×
“injection of a rAAV serotype 2–AAT vector (11, 12) and subsequently using a cross-packaged rAAV serotype 1–AAT vector (rAAV1-AAT) in phase I and phase II clinical trials (13, 14) Published results from both of the rAAV1-AAT trials have shown a dose-dependent increase in serum levels of wild-type–specific AAT (M-AAT) l…”
MethodSelf-citationArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117 · cited 1×
“How this would affect the results is difficult to predict, although some preclinical data suggest that the amount of transgene expression observed for any given dose of vector could be higher with a regional vascular delivery method (23, 24).”
Sakaguchi, S. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030012 · Cited by 109 · cited 1×
“org 7 the nonspecific activation of Tregs through Toll-like receptor signaling or Treg stimulation by cross-reactive epitopes (27, 28).”
BackgroundRodino-Klapac, L. R., Janssen, P. M., Montgomery, C. L., Coley, B. D., Chicoine, L. G., Clark, K. R., & Mendell, J. R. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-45 · Cited by 104 · cited 2×
“35 ml each, further increases in the dose will likely require some form of regional vascular delivery (22, 23).”
Toromanoff, A., Chérel, Y., Guilbaud, M., Penaud-Budloo, M., Snyder, R. O., Haskins, M. E., Deschamps, J.-Y., Guigand, L., Podevin, G., Arruda, V. R., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.87 · Cited by 99 · cited 3×
“How this would affect the results is difficult to predict, although some preclinical data suggest that the amount of transgene expression observed for any given dose of vector could be higher with a regional vascular delivery method (23, 24).”
Stieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Meur, G. L., Weber, M., Deschamps, J.-Y., Lorenz, B., Moullier, P., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.283 · Cited by 88 · cited 1×
“This finding is consistent with an earlier study that documented the detection of rAAV particles up to 6 years after administration in the retina of dogs and nonhuman primates (25) and may explain why Tregs would continue to reside within the injected muscle months after administration.”
ResultEpigenetic quantification of tumor-infiltrating T-lymphocytes
Sehouli, J., Loddenkemper, C., Cornu, T., Schwachula, T., Hoffmüller, U., Grützkau, A., Lohneis, P., Dickhaus, T., Gröne, J., Kruschewski, M., et al. (2011) · Epigenetics · doi:10.4161/epi.6.2.13755 · Cited by 83 · cited 1×
“Epigenetic T cell analysis was performed as previously described (38).”
Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data
Emerson, R., Sherwood, A., Desmarais, C., Malhotra, S., Phippard, D., & Robins, H. S. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.02.002 · Cited by 78 · cited 1×
“TCRV β usage was also determined for each clone, as previously described (39, 40).”
Li, S., Floess, S., Hamann, A., Gaudieri, S., Lucas, A., Hellard, M., Roberts, S., Paukovic, G., Plebanski, M., Loveland, B. E., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000707 · Cited by 71 · cited 1×
“While the mechanism remains elusive, it is clear that virus-specific natural Tregs allowing viral persistence have been observed in humans with chronic hepatitis C virus (29, 30).”
BackgroundToromanoff, A., Adjali, O., Larcher, T., Hill, M., Guigand, L., Chenuaud, P., Deschamps, J.-Y., Gauthier, O., Blancho, G., Vanhove, B., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.251 · Cited by 61 · cited 1×
“However, given the scalability of rAAV vector production (34), the availability of clinically tolerable limb infusion methods (22, 23, 35, 36), and the relatively modest levels of immune suppression that may have a salient effect (6), it would seem that trials designed to achieve therapeutic levels of serum AAT should…”
BackgroundChulay, J. D., Ye, G.-J., Thomas, D. L., Knop, D. R., Benson, J. M., Hutt, J. A., Wang, G., Humphries, M., & Flotte, T. R. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.118 · Cited by 60 · cited 2×
“recombinant HSV complementation system (37).”
Self-citationFan, Z., Kocis, K., Valley, R., Howard, J. F., Chopra, M., An, H., Lin, W., Muenzer, J., & Powers, W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.137 · Cited by 55 · cited 1×
“However, given the scalability of rAAV vector production (34), the availability of clinically tolerable limb infusion methods (22, 23, 35, 36), and the relatively modest levels of immune suppression that may have a salient effect (6), it would seem that trials designed to achieve therapeutic levels of serum AAT should…”
BackgroundCoexpression of CD25 and OX40 (CD134) Receptors Delineates Autoreactive T-cells in Type 1 Diabetes
Endl, J., Rosinger, S., Schwarz, B., Friedrich, S.-O., Rothe, G., Karges, W., Schlosser, M., Eiermann, T., Schendel, D. J., & Boehm, B. O. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0387 · Cited by 48 · cited 2×
“Two days after stimulation, the cells were analyzed by flow cytometry, Tregs were gated by coexpression of the transcription factors FOXP3 and Helios, and all subsets were then analyzed for expression of CD25 and OX40 as indicators of antigen-specific activation, as previously described (16).”
BackgroundMethodActivation of CD4 + CD25 + regulatory T cell suppressor function by analogs of the selecting peptide
Larkin, J., Picca, C. C., & Caton, A. J. (2006) · European Journal of Immunology · doi:10.1002/eji.200636577 · Cited by 28 · cited 1×
“org 7 the nonspecific activation of Tregs through Toll-like receptor signaling or Treg stimulation by cross-reactive epitopes (27, 28).”
BackgroundMezzina, M., & Merten, O. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-095-9_9 · Cited by 27 · cited 1×
“However, given the scalability of rAAV vector production (34), the availability of clinically tolerable limb infusion methods (22, 23, 35, 36), and the relatively modest levels of immune suppression that may have a salient effect (6), it would seem that trials designed to achieve therapeutic levels of serum AAT should…”
BackgroundDevelopment, validation and use of ELISA for antibodies to human alpha-1 antitrypsin
Ye, G.-J., Oshins, R. A., Rouhani, F. N., Brantly, M., & Chulay, J. D. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.11.008 · Cited by 8
Self-citation
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“Moreover, CD4CD25FoxP3 regulatory T cells (Tregs) infiltrated the tissue and likely contributed to the resolution of this immune response, while CD8 T cells acquired a phenotype resembling exhausted T cells.(62) Similar observations were made in muscle gene transfer for lipoprotein lipase deficiency.”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Greene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Self-citationKeeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Self-citation
Metadata
- Authors
- Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., Campbell-Thompson, M., Fu, A. D., Yachnis, A., Knop, D. R., Ye, G.-J., Brantly, M., Calcedo, R., Somanathan, S., Richman, L. P., Vonderheide, R. H., Hulme, M. A., Brusko, T. M., Wilson, J. M., & Flotte, T. R.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Applied Genetic Technologies (United States) (US)
- Cincinnati Children's Hospital Medical Center (US)
- National Jewish Health (US)
- Beaumont Hospital (IE)
- University of Florida Health (US)
- University of Pennsylvania (US)
- Corresponding author
- Flotte, Terence R.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-11-15
- Volume
- 123
- Issue
- 12
- Pages
- 5310-5318
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3859421
- OpenAlex
- W2087513462
- Cited by
- 169
- References
- 40
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 9 · 2022: 9 · 2021: 19 · 2020: 9 · 2019: 16 · 2018: 10 · 2017: 23 · 2016: 11 · 2015: 17 · 2014: 13 · 2013: 1
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000161)
- U.S. Food and Drug Administration (R01FD003896)
- National Heart, Lung, and Blood Institute (R01HL069877, HL 69877)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- recombinant adeno-associated virus, AAV1, alpha-1 antitrypsin deficiency, regulatory T cells, natural regulatory T cells, transgene expression persistence, gene therapy, T cell receptor V beta repertoire, AAV capsid, intramuscular injection, immunomodulation, muscle fibers
- MeSH terms
- Dependovirus, alpha 1-Antitrypsin, Biopsy, Capsid, Clone Cells, Gene Expression Regulation, Genetic Vectors, Humans, Injections, Intramuscular, Lymphocyte Activation, Recombinant Fusion Proteins, Genetic Therapy, Gene Rearrangement, beta-Chain T-Cell Antigen Receptor, Receptors, Antigen, T-Cell, alpha-beta, Muscle, Skeletal, Transgenes, alpha 1-Antitrypsin Deficiency, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.